ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical trial NCT03742921 · COMPLETED

Trial details

NCT number: NCT03742921
Sponsor: Celgene
Status: COMPLETED
Study type: OBSERVATIONAL

Lymphoma, T-Cell, Peripheral

Start date: 2019-02-04
Primary completion: 2023-10-31
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.